| Management of systemic lupus erythematosus |
|
Yong-Gil Kim |
|
가톨릭대학교 의과대학 1내과학교실, 2진단방사선과교실, 3병원병리과교실 |
| 전신 홍반 루푸스의 치료 |
|
김용길 |
|
Departments of 1Internal Medicine, 2Radiology and 3Hospital Pathology, The Catholic University of Korea College of Medicine, Seoul, Korea |
|
|
|
|
| Abstract |
|
Systemic lupus erythematosus (SLE) is an autoimmune disorder which affects the musculoskelectal system, skin, kidney, central nervous system, gastrointestinal tract, and vascular system. The therapeutic level depends on the severity of SLE activity and affected organ damage. The prognosis of SLE has greatly improved since treatment regimens combining corticosteroids and immunosuppressive agents have been widely adopted in therapeutic strategies. Immune suppression is evidently effective, however, sometimes leads to higher susceptibility to infectious and malignant diseases. Toxic effects and unexpectedly fatal complications of current therapies have been progressively reported. Currently, identifying novel molecular targets such as hyperactive B cells could be an important issue in the treatment of SLE. The aim of this review is the introduction of previous adopted therapies as well as emerging pharmacological options. (Korean J Med 78:425-429, 2010) |
| Key Words:
Systemic lupus erythematosus; Treatment; Immunosuppressive agent |
|
PDF Links
Full text via DOI
Download Citation
